A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19

Ran Abuhasira, Irit Ayalon-Dangur, Neta Zaslavsky, Ronit Koren, Mally Keller, Dror Dicker, Alon Grossman, Ran Abuhasira, Irit Ayalon-Dangur, Neta Zaslavsky, Ronit Koren, Mally Keller, Dror Dicker, Alon Grossman

Abstract

Objective: To assess the effect of linagliptin vs. standard therapy in improving clinical outcomes in patients hospitalized with diabetes and coronavirus disease 2019 (COVID-19).

Materials and methods: We did an open-label, prospective, multicenter, randomized clinical trial in 3 Israeli hospitals between October 1, 2020, and April 4, 2021. Eligible patients were adults with type 2 diabetes mellitus and a diagnosis of COVID-19. A total of 64 patients, 32 in each group, were randomized to receive linagliptin 5 mg PO daily throughout the hospitalization or standard of care therapy. The primary outcome was time to clinical improvement within 28 days after randomization, defined as a 2-point reduction on an ordinal scale ranging from 0 (discharged without disease) to 8 (death).

Results: The mean age was 67 ± 14 years, and most patients were male (59.4%). Median time to clinical improvement was 7 days (interquartile range (IQR) 3.5-15) in the linagliptin group compared with 8 days (IQR 3.5-28) in the standard of care group (hazard ratio, 1.22; 95% CI, 0.70-2.15; p = 0.49). In-hospital mortality was 5 (15.6%) and 8 (25.0%) in the linagliptin and standard of care groups, respectively (odds ratio, 0.56; 95% CI, 0.16-1.93). The trial was prematurely terminated due to the control of the COVID-19 outbreak in Israel.

Conclusions: In this randomized clinical trial of hospitalized adult patients with diabetes and COVID-19 who received linagliptin, there was no difference in the time to clinical improvement compared with the standard of care.

Clinical trial registration: ClinicalTrials.gov, identifier NCT04371978.

Keywords: COVID-19; DPP-4 inhibitors; diabetes; hospital management; linagliptin.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Abuhasira, Ayalon-Dangur, Zaslavsky, Koren, Keller, Dicker and Grossman.

Figures

Figure 1
Figure 1
Flowchart of the study.
Figure 2
Figure 2
Kaplan–Meier estimates of cumulative clinical improvement.

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A Novel Coronavirus From Patients With Pneumonia in China, 2019. N Engl J Med (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
    1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032
    1. Maddaloni E, Buzzetti R. Covid-19 and Diabetes Mellitus: Unveiling the Interaction of Two Pandemics. Diabetes Metab Res Rev (2020) 36:e3321. doi: 10.1002/dmrr.3321
    1. Iacobellis G. COVID-19 and Diabetes: Can DPP4 Inhibition Play a Role? Diabetes Res Clin Pract (2020) 162:108125. doi: 10.1016/j.diabres.2020.108125
    1. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The Effect of Corticosteroid Treatment on Patients With Coronavirus Infection: A Systematic Review and Meta-Analysis. J Infect (2020) 81:e13–20. doi: 10.1016/j.jinf.2020.03.062
    1. Siemieniuk RAC, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Pardo-Hernandez H, et al. . Drug Treatments for Covid-19: Living Systematic Review and Network Meta-Analysis. BMJ (2020) 370:m2980. doi: 10.1136/bmj.m2980
    1. Piscoya A, Ng-Sueng LF, del Riego AP, Cerna-Viacava R, Pasupuleti V, Roman YM, et al. . Efficacy and Harms of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. PloS One (2020) 15:e0243705. doi: 10.1371/journal.pone.0243705
    1. Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, et al. . Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol (2021) 73:36–47. doi: 10.1002/art.41469
    1. COVID-19 Treatment Guidelines. Available at: (Accessed May 13, 2021).
    1. Shao S, Xu QQ, Yu X, Pan R, Chen Y. Dipeptidyl Peptidase 4 Inhibitors and Their Potential Immune Modulatory Functions. Pharmacol Ther (2020) 209:107503. doi: 10.1016/j.pharmthera.2020.107503
    1. Zou H, Zhu N, Li S. The Emerging Role of Dipeptidyl-Peptidase-4 as a Therapeutic Target in Lung Disease. Expert Opin Ther Targets (2020) 24:147–53. doi: 10.1080/14728222.2020.1721468
    1. Stalin Raj V, Mou H, Smits SL, W Dekkers DH, Müller MA, Dijkman R, et al. . Dipeptidyl Peptidase 4 Is a Functional Receptor for the Emerging Human Coronavirus-EMC. Nature (2013) 495:251–4. doi: 10.1038/nature12005
    1. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) Coronavirus: Glycan Shield and Structure Prediction of Spike Glycoprotein and Its Interaction With Human CD26. Emerg Microbes Infect (2020) 9:601–4. doi: 10.1080/22221751.2020.1739565
    1. Yamada Y, Nishikawa S, Tanaka S, Hamaji M, Nakajima D, Ohsumi A, et al. . CD26/DPP4 Inhibitor: A Novel Prophylactic Drug for Chronic Allograft Dysfunction After Clinical Lung Transplantation. J Hear Lung Transplant (2020) 39:S66. doi: 10.1016/j.healun.2020.01.1269
    1. Scheen AJ. DPP-4 Inhibition and COVID-19: From Initial Concerns to Recent Expectations. Diabetes Metab (2021) 47:101213. doi: 10.1016/j.diabet.2020.11.005
    1. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl Peptidase-4 (DPP4) Inhibition in COVID-19. Acta Diabetol (2020) 57:779–83. doi: 10.1007/s00592-020-01539-z
    1. Solerte SB, D’Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, et al. . Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care (2020) 42:dc201521. doi: 10.2337/dc20-1521
    1. Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E, et al. . Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With Covid-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care (2020) 43:3042–9. doi: 10.2337/dc20-1340
    1. Bonora BM, Avogaro A, Fadini GP. Disentangling Conflicting Evidence on DPP-4 Inhibitors and Outcomes of COVID-19: Narrative Review and Meta-Analysis. J Endocrinol Invest (2021) 1:1–8. doi: 10.1007/s40618-021-01515-6
    1. FDA . Drug Approval Package: Tradjenta (Linagliptin) (2011). Available at: (Accessed April 13, 2020).
    1. Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, et al. . Linagliptin Versus Sitagliptin in Patients With Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Clinical Trials. DARU J Pharm Sci (2017) 25:25–23. doi: 10.1186/s40199-017-0189-6
    1. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. . Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation (2019) 139:351–61. doi: 10.1161/CIRCULATIONAHA.118.038352
    1. Association AD. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. Diabetes Care (2021) 44:S211–20. doi: 10.2337/dc21-s015
    1. Association AD. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020. Diabetes Care (2020) 43:S193–202. doi: 10.2337/DC20-S015
    1. Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, et al. . Therapeutic Strategies to Fight COVID-19: Which Is the Status Artis? Br J Pharmacol (2021) 1-21:bph.15452. doi: 10.1111/bph.15452
    1. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med (2021) 384:1412–23. doi: 10.1056/nejmoa2101765
    1. Leshem E, Wilder-Smith A. COVID-19 Vaccine Impact in Israel and a Way Out of the Pandemic. Lancet (London England) (2021) 397:1783–5. doi: 10.1016/S0140-6736(21)01018-7
    1. Association AD. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care (2021) 44:S15–33. doi: 10.2337/DC21-S002
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir–Ritonavir in Adults Hospitalized With Severe Covid-19. N Engl J Med (2020) 382:1787–99. doi: 10.1056/nejmoa2001282
    1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet (2020) 395:1569–78. doi: 10.1016/S0140-6736(20)31022-9
    1. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. . Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc (2021) 325:1426–35. doi: 10.1001/jama.2021.3071
    1. World Health Organization . WHO R&D Blueprint Novel Coronavirus COVID-19 Phase IIb/III Vaccine Trial Synopsis. Geneva, Switzerland: World Health Organization; (2020).
    1. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. . Tocilizumab in Patients Hospitalized With Covid-19 Pneumonia. N Engl J Med (2021) 384:20–30. doi: 10.1056/nejmoa2030340
    1. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med (2021) 181:24–31. doi: 10.1001/jamainternmed.2020.6615
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. . Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med (2020) 383:1813–26. doi: 10.1056/nejmoa2007764
    1. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. . Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries. Am J Epidemiol (2011) 173:676–82. doi: 10.1093/aje/kwq433
    1. Lisker G, Narasimhan M, Greenberg H, Ramdeo R, McGinn T. Ambulatory Management of Moderate to High Risk COVID-19 Patients: The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol. Home Heal Care Manag Pract (2021) 33:49–53. doi: 10.1177/1084822320964196
    1. Strollo R, Pozzilli P. DPP4 Inhibition: Preventing SARS-CoV-2 Infection and/or Progression of COVID-19? Diabetes Metab Res Rev (2020) 36:e3330. doi: 10.1002/dmrr.3330
    1. Parasher A. COVID-19: Current Understanding of Its Pathophysiology, Clinical Presentation and Treatment. Postgrad Med J (2020) 97:postgradmedj–2020–138577. doi: 10.1136/postgradmedj-2020-138577
    1. Shao S, Yang Q, Pan R, Yu X, Chen Y. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol (Lausanne) (2021) 12:731974/BIBTEX. doi: 10.3389/FENDO.2021.731974/BIBTEX
    1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA (2020) 323(18):1824–36. doi: 10.1001/jama.2020.6019
    1. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and Comorbidities: A Role for Dipeptidyl Peptidase 4 (DPP4) in Disease Severity? J Diabetes (2020) 12:649–58. doi: 10.1111/1753-0407.13052
    1. Valencia I, Peiró C, Lorenzo Ó, Sánchez-Ferrer CF, Eckel J, Romacho T. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? Front Pharmacol (2020) 11:1161. doi: 10.3389/FPHAR.2020.01161
    1. Gomes GKA, de Camargos Ramos AI, de Sousa CT, Sanches C, Pereira ML, Baldoni AO. Linagliptin Safety Profile: A Systematic Review. Prim Care Diabetes (2018) 12:477–90. doi: 10.1016/j.pcd.2018.04.006

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe